Gallbladder Cancer Diagnostic Workup
Begin with abdominal ultrasound as the initial screening test, followed by contrast-enhanced CT of chest, abdomen, and pelvis for staging, with tissue diagnosis obtained via EUS-guided biopsy or surgical specimen when resection is planned.
Initial Imaging Approach
Ultrasound is the first-line investigation for suspected gallbladder cancer 1, 2. This allows:
- Risk stratification of wall thickening patterns
- Evaluation of polypoidal lesions
- Detection of gallbladder masses
- Assessment of liver involvement and biliary obstruction
Ultrasound Risk Stratification for Polyps:
- <5 mm: Generally ignored, no follow-up needed
- 6-10 mm: Surveillance ultrasound if no other risk factors 3
- >10 mm: Surgical consideration required 2, 3
- Any polyp with vascular stalk on imaging: Resection indicated regardless of size 2
Cross-Sectional Imaging for Staging
CT scan (multi-detector or helical) of abdomen and pelvis is the test of choice for comprehensive staging 4, 2, 5. This evaluates:
- Primary tumor extent and liver invasion
- Regional and distant lymphadenopathy (aim to identify at least 6 nodes for adequate staging)
- Peritoneal metastases
- Distant metastases
Add chest CT or chest X-ray to complete metastatic workup 2, 5.
When to Use MRI/MRCP:
- Better delineation of biliary system involvement 4, 1
- Problem-solving when distinction from benign lesions is challenging
- Advanced techniques (DWI, dynamic contrast-enhanced) for difficult cases 1
Important caveat: MRI/MRCP and PET-CT are not recommended for all patients - reserve for specific clinical scenarios where standard imaging is inconclusive 5.
Tissue Diagnosis Strategy
For Potentially Resectable Disease:
Obtain tissue at time of surgical resection - avoid preoperative biopsy due to tumor seeding risk 4, 2. The risk of needle tract seeding is very low but real, and decisions for preoperative biopsy must be made in multidisciplinary settings 4.
For Advanced/Unresectable Disease:
EUS-guided FNA or FNB is preferred for:
- Primary tumor sampling (depending on location)
- Regional lymph node biopsy if enlarged
- High diagnostic accuracy (sensitivity 98.82%, specificity 87.23%) 6
Alternative approaches if EUS unavailable:
- Percutaneous biopsy under imaging guidance
- Laparoscopic biopsy during staging laparoscopy
Tumor Markers
CA 19-9 and CEA should be measured but are adjunctive, not diagnostic 7:
- CA 19-9: Elevated in up to 85% of gallbladder cancer; >100 U/ml has 75% sensitivity and 80% specificity
- CEA: Raised in ~30% of cases; more variable than CA 19-9
- Combined use improves diagnostic accuracy 7
Critical limitation: These markers are non-specific and can be elevated in benign biliary obstruction, chronic liver disease, and other malignancies 8.
Essential Laboratory Tests
- Complete blood count (note: platelet counts may be reduced in adenocarcinoma and correlate with CA 19-9 7)
- Liver function tests (bilirubin, AST, ALT, alkaline phosphatase, albumin)
- Renal function (BUN, creatinine)
- Coagulation profile (PT/INR)
Staging Laparoscopy
Perform diagnostic laparoscopy before planned resection in patients with imaging-suggested resectable disease 8, 2. This detects:
- Peritoneal metastases (present in 10-20% at presentation)
- Superficial liver metastases
- Unsuspected N2 nodal disease (which contraindicates radical resection)
Pathological Examination Requirements
All cholecystectomy specimens must be examined histopathologically 2, 5:
- Minimum 3 sections evaluated microscopically
- Cystic duct margin assessed
- Specimens with dysplasia or cancer require extensive sampling
- Operating surgeon should open and examine specimen before sending to pathology 5
Common Pitfalls to Avoid
- Do not rely on tumor markers alone - imaging findings of classic enhancement patterns are more definitive
- Do not skip staging laparoscopy in apparently resectable disease - up to 50% have lymph node involvement at presentation 8
- Do not perform transperitoneal biopsy in potentially resectable tumors without multidisciplinary discussion
- Do not assume negative cytology excludes malignancy - sensitivity of brush cytology is only 30-40% even with combined techniques
Molecular Testing
For advanced disease, obtain tissue for next-generation sequencing to identify actionable targets (IDH1, HER2/ERBB2, BRAF mutations, FGFR2 and NTRK fusions) 4. This guides targeted therapy options in the metastatic setting.